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Organisms adapt to infectious agents by
developing protective responses, and con-
versely, infectious agents develop adaptive
countermeasures to these responses. Host
defenses against infectious agents include
adaptive and innate immune responses
(e.g., natural killer cells, Toll-like recep-
tors, and interferons). Recently, additional
host defense systems against viruses have
been identified. These include the TRIM
[1], RIGI/MDA5 [2], Bst2/tetherin [3,4],
and APOBEC3 (A3) [5] proteins. Many of
these anti-viral defense mechanisms were
identified through the discovery of viral
gene products that counteract their action,
and thus it has been proposed that only
viruses resistant to host-encoded restriction
factors persist. However, recent in vivo
work in the murine system has indicated
that endogenous A3 proteins play impor-
tant roles in limiting pathogenicity by
murine viruses even though they only
partially restrict infection [6–8]. Here I
argue that these recent studies emphasize
the critical importance of studying natural
pathogenic viruses and host restriction
factors in vivo.
A3 proteins belong to a family of genes
that encode DNA- and RNA-editing
enzymes and confer innate immunity to
HIV-1 and perhaps other viruses, such as
hepatitis B virus (HBV) and human
papilloma virus (HPV) [9,10]. The A3
genes arose through gene duplication of a
single-copy primordial gene, are found in
a tandem array, and have expanded or
contracted in different species [11]; the
human genome encodes seven A3 (hA3)
genes, the feline four genes [12], the horse
six genes [13], artiodactyls species two to
three genes [14], and the mouse genome a
single A3 (mA3) gene [15]. The A3 genes in
general show a high degree of polymor-
phic variation, suggesting that they are
under strong selective pressure [8,12,16–
19]. Additionally, alternatively spliced
RNAs with the potential for generating
different A3 proteins have been found in
the mouse (Figure 1A; see below), felines
[12], and artiodactyls [14].
hA3G, the first identified family mem-
ber, was discovered because of its interac-
tion with the HIV-1 virion infectivity
factor (Vif) [5]. hA3G and subsequently
hA3F were shown to inhibit HIV-1 lacking
the vif gene. In vif-deficient HIV-1 pro-
ducer cells, both hA3G and hA3F are
packaged into progeny virions via interac-
tion with the nucleocapsid (NC) protein
and viral RNA. Once packaged, hA3
proteins inhibit infection in target cells by
deaminating deoxycytidine residues on the
DNA minus strand following reverse
transcription, inducing G to A hypermuta-
tion in newly synthesized HIV-1 DNA. A3
proteins also inhibit replication by cytidine
deaminase (CDA)-independent mecha-
nisms [20]. In cells infected with vif+
HIV-1, Vif binds hA3G and hA3F and
targets these proteins for ubiquitinylation
and degradation in the proteosome, there-
by overcoming the anti-viral activity [21–
24]. Simian immunodeficiency viruses
(SIVs) also encode Vif proteins, while
foamy viruses (FVs) encode a protein
(Bet) that interacts with A3G and prevents
its packaging via a mechanism that is
apparently different from that of Vif [25–
27]. There are also a large number of
studies demonstrating that A3 proteins
inhibit transposition of human and mouse
retroelements, such as LINE-1, Alu,
MusD, human endogenous retroviruses
(HERVs), and IAPs [28–34]. Although
no study has directly examined the effect
of A3 proteins on endogenous copies of
these elements, both HERV and endoge-
nous murine leukemia virus (MLV) se-
quences bear signatures of cytidine deam-
ination [35–37].
Several studies have examined packag-
ing of A3 proteins from different species
into retroviruses endemic to the species
using transfected tissue culture cells and
have suggested that these viruses are
resistant to the A3 proteins of their natural
hosts. For example, it has been shown that
human T cell leukemia virus I (HTLVI),
Mason Pfizer monkey virus (MPMV), and
MLV do not efficiently package human,
monkey, or mouse A3 proteins, respec-
tively, because of weak interactions be-
tween the NC proteins and the host A3
[38–46], although other studies have
shown some packaging of host A3 proteins
by HTLVI and MLV as well as viral
restriction [47–50]. The MLV protease
may also degrade mA3, thereby prevent-
ing its anti-viral function [45]. More
recently, equine infectious anemia virus
was shown to package several horse A3
proteins but these did not diminish
infection as effectively as human A3
proteins [13].
In contrast to studies demonstrating
that endogenous A3 proteins do not
restrict retroviruses that infect the same
species, there are many examples of cross-
species restriction in cultured cells. Human
A3B and A3C restrict SIV [51] and hA3G
restricts Rous sarcoma virus, feline FV,
MLV, and mouse mammary tumor virus
(MMTV) [6,25,42–44,48,52–54]. Indeed,
several human A3 proteins including
hA3G have been shown to restrict MLV
via deamination [42,43,54,55], although
to a lesser extent than HIV-1 [50]. There
is also species-specific degradation of
hA3G proteins by different Vifs. For
example, Vifs encoded by SIVs that infect
humans (chimpanzees and sooty manga-
beys) can cause the degradation of hA3G,
while Vifs from SIVs that don’t infect
humans (African green monkeys) don’t
interact with hA3G [56–59]. Additionally,
mouse A3, which does not bind Vif,
restricts HIV-1 infection [48], MPMV
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dependent mechanism. Thus, it has been
proposed that one role for A3 proteins is to
prevent zoonoses rather than to restrict
natural infections [9].
However, the studies showing that A3
proteins do not restrict viruses that infect
the same species need to be re-evaluated in
light of several recent studies with two
mouse viruses, MMTV and MLV. These
in vivo studies examined the role of A3 in
the resistance and susceptibility to infec-
tion in different inbred strains of mice and
in mice with targeted deletion of the mA3
gene and clearly demonstrate that the host
A3 protein plays a role in virus infection
and, more importantly, in virus-mediated
pathogenesis.
In the first of these studies, our lab
tested whether knockout mice that lack a
functional A3 gene were susceptible to
infection with MMTV [6]. MMTV is a
betaretrovirus that is normally acquired
through milk by suckling neonates and
first infects cells in the lymphoid compart-
ment followed by transmission to the
mammary epithelial cells [60]. We infect-
ed mA3+/+ and mA32/2 mice and
showed that mA32/2 mice had higher
levels of initial infection compared to their
wild-type littermates and moreover, that
virus spread was more rapid and extensive.
We have also found that MMTV-infected
mA32/2 mice develop mammary tumors
more rapidly (C. Okeoma and S. Ross,
unpublished data). These findings demon-
strate that mA3 provides partial protection
to mice against MMTV infection and
represent the first demonstration to our
knowledge that A3 proteins function
during in vivo retroviral infection.
Two groups more recently demonstrat-
ed that mA3 also restricts Friend MLV (F-
MLV) infection and virus-induced ery-
throproliferation [7,8]. In the 1970s,
genetic crosses between various strains of
inbred mice were carried out as a means of
identifying genetic loci that would confer
susceptibility or resistance to F-MLV [61].
The recovery from Friend virus 3 (Rfv3)
locus was subsequently found to affect the
ability of resistant mice, such as C57BL/6,
to recover from virus infection, at least in
part through the production of a high-level
antibody response [62,63]. Mapping stud-
ies placed Rfv3 to a 0.83 centimorgan
region of chromosome 15, close to the
APOBEC3 locus [64,65]. The Greene and
Miyazawa groups tested whether Rfv3 and
mA3 were one and the same, and their
data suggest that this may be the case
[7,8]. Both groups showed that mA32/2
mice were more highly infected by F-MLV
than were mA3+/+ mice, and when F-
MLV-susceptible (BALB/c) mice were
crossed with mA32/2 mice and infected
with virus, the F1 progeny had high virus
titers, did not develop a strong neutralizing
antibody response, and showed increased
erythroid cell proliferation characteristic of
F-MLV-mediated disease. Conversely,
mA32/2 X C57BL/6 F1 mice looked
like their resistant parent, with low viremia
and high antibody production.
The two groups differed in their con-
clusions regarding the mechanism of A3-
mediated resistance. There are a number
of differences between the A3 alleles in F-
MLV-resistant and –susceptible mice,
leading to differences in mRNA expression
levels, alternative splicing of the mRNA,
and amino acid polymorphisms
[7,8,45,65]. C57BL/6 mice predominant-
ly express a Dexon 5 variant of mA3
(Figure 1A) [7,8,66]. Using a transfection/
infection assay with hybrid A3 molecules,
Takeda and colleagues mapped the ability
of the C57BL6-derived allele to restrict
infection to polymorphic amino acids in
the N-terminal 192 amino acid region and
Figure 1. Polymorphisms in APOBEC 3 Genes. (A) Different splice variants and polymorphic exons found in different inbred mouse strains. Blue
boxes denote exons found in inbred strains such as BALB/c and 129; red boxes denote exons with polymorphic amino acid differences in C57BL-
derived strains. The table denotes the relative expression levels of the different splice variants expressed in the different strains, as well as the
susceptibility (S) or resistance (R) to F-MLV infection. Data taken from references [7,8,65,66]. (B) Different A3 alleles found in human populations. At
least seven SNP polymorphisms have been found in the A3G genes in humans, although only one polymorphic A3G allele, H186R, has been
associated with increased susceptibility to HIV-1-mediated disease [69]. Also shown is the presumed recombination event leading to the deletion of
part of A3B in some individuals and a fused hA3A/3B gene [71].
doi:10.1371/journal.ppat.1000347.g001
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Santiago and colleagues suggested that a
lack of exon 2 in the mA3 made in BALB/
c (or A.BY) susceptible mice contributes to
the inability of mA3 from these back-
grounds to inhibit infection, although this
transcript was not detected in the studies
by Takeda et al. and our lab has more
recently found that the major transcript in
BALB/c mice contains exon 2 [66].
C57BL/6 mice also express higher levels
of A3 RNA than BALB/c mice [7,65,66].
We also found that the C57BL/6 mA3
allele restricts MMTV infection more
effectively than that encoded in BALB/c
mice [66]. Which of these differences
contribute to resistance to virus infection
in vivo awaits the creation of transgenic or
knock-in mice with the different alleles to
directly test their efficacy in restricting F-
MLV and MMTV.
Importantly, these studies demonstrate
that the tissue culture experiments that
examine the role of host restriction factors
can underestimate the role that these
restriction factors play in vivo. The numer-
ous studies regarding mA3’s effect on MLV
infection in cultured cells are conflicting,
providing evidence for and against a role in
restriction [43,44,49,50,67]. Although the
tissue culture studies predominantly exam-
inedtheroleofmA3onMoloneyMLV(M-
MLV) rather than F-MLV, a recent study
also shows that mA32/2 mice are more
susceptible than mA3+/+ mice to infection
and lymphoma induction by M-MLV [68].
While the F-MLV studies do not defini-
tively prove that Rfv3 is mA3, the fact that
mA32/2 mice are more susceptible to
infection by at least two murine retrovirus-
es, MMTV and MLV, and that the loss of
this gene in vivo leads to increased
pathogenesis by these viruses, provides
strong support that this host-encoded
restriction factor does function against a
natural pathogen.
What does this mean for HIV-1 and
other human pathogens and the role that
hA3 proteins play in restricting HIV-1
infection? There is increasing genetic
evidence that A3 proteins protect against
infection by HIV-1 and other viruses.
Indeed, one of the alleles that has been
linked to individuals who have received
multiple exposures to HIV but remained
sero-negative maps to chromosome
22q12-13, which contains the human A3
family member genes [64,65]. One A3G
polymorphism, H16R, is associated with
AIDS progression and declining CD4 T
cells, although the in vitro anti-viral
activity of the two alleles was the same
[69]. Several human A3 genes, particularly
A3G and A3H, are highly polymorphic,
suggesting positive selection by viruses or
retroelements [18,19,70], and there is a
known deletion in the A3B locus that leads
to a fused hA3A/3B gene [71] (Figure 1B).
Although alternative splicing has been
shown to generate different A3 proteins
in mice, artiodactyls, and felines, thus far
only APOBEC3H has been shown to
undergo alternative splicing in humans
[72]. This represents another potential
means of generating A3 proteins that more
effectively restrict infection and needs to
be more thoroughly examined for the
different human genes.
The mouse studies underscore the
importance of using in vivo models to
understand host restriction factors and
their importance in limiting viral patho-
genesis. Unfortunately, the lack of a good
animal model means we can at present
only infer that A3G or other A3 molecules
are retained in the genome as anti-HIV-1
(or other viruses) restriction factors in
humans and other species. In the absence
of being able to test species-specific A3
molecules in vivo against species-endemic
viruses, it is critical to look for genetic
associations between polymorphic A3 al-
leles and resistance to infection to HIV-1,
HTLVI, HBV, HPV, and other viruses
whose infection may be affected by A3
proteins in vivo.
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